Q.1
Revenue growth of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd revenue growth is 42.6% for FY-2025 , which is above its 5 year CAGR of 21.2% , indicating faster growth.
Q.2
Gross Profit margin of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Gross profit margin which is the profit after deduction of direct costs, is 17% for FY-2025 , which is above its 5 year median of 13.2% , indicating increasing margins.
Q.3
Operating Profit Margin of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 18.24% for FY-2025 , which is above its 5 year median of 14.84% indicating increasing margins.
Q.4
Net Profit Margin of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Net Profit Margin is 15.67% for FY-2025 , is above with its 5 year median of 11.73%, indicating increasing margins.
|
Current Level |
Historic Median |
|
Gross Profit Margin |
17 |
13.2 |
|
Operating Profit Margin |
18.24 |
14.84 |
|
Net Profit Margin |
15.67 |
11.73 |
Q.5
Return on Asset of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Return on Asset is 17.98%, which is above its 5 year historical median of 11.67%, indicating improved asset utilization efficiency.
Q.6
Return on Equity (ROE) of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Return on equity is 23.03% for FY-2025 , which is above its historical median of 17.34%, indicating the business is making better use of its shareholders capital.
Q.7
Return on capital employed (ROCE) of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Return on capital employed is 21.15% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.
Q.8
Cash conversion cycle of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Cash conversion cycle is 265 days, below its historical median of 265 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
|
Current Level |
Historic Median |
|
Asset Turnover |
1.15 |
1.02 |
|
ROE |
23.03 |
17.34 |
|
ROCE |
21.15 |
15.86 |
|
Cash Conversion Cycle |
265 days |
265 days |
Q.9
Debt to Equity ratio of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Debt-to-Equity ratio is 0.19 , which is above with the industry average of 0.1 , indicating higher debt levels in the industry.
Q.10
Debt to cash flow from operations of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Debt to cash flow from operations is 10.45 , which is at a unhealthy level.